Cargando…
Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer
Lysyl Oxidase-like 2 (LOXL2), a member of the lysyl oxidase family of amine oxidases is known to be important in normal tissue development and homeostasis, as well as the onset and progression of solid tumors. Here we tested the anti-tumor properties of two generations of novel small molecule LOXL2...
Autores principales: | Chang, Joan, Lucas, Morghan C., Leonte, Lidia E., Garcia-Montolio, Marc, Singh, Lukram Babloo, Findlay, Alison D., Deodhar, Mandar, Foot, Jonathan S., Jarolimek, Wolfgang, Timpson, Paul, Erler, Janine T., Cox, Thomas R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432238/ https://www.ncbi.nlm.nih.gov/pubmed/28199967 http://dx.doi.org/10.18632/oncotarget.15257 |
Ejemplares similares
-
An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies
por: Findlay, Alison, et al.
Publicado: (2021) -
Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis
por: Madsen, Chris D, et al.
Publicado: (2015) -
LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling
por: Chang, Joan, et al.
Publicado: (2013) -
The lysyl oxidase like 2/3 enzymatic inhibitor, PXS‐5153A, reduces crosslinks and ameliorates fibrosis
por: Schilter, Heidi, et al.
Publicado: (2018) -
The role of lysyl oxidase, the extracellular matrix and the pre-metastatic niche in bone metastasis()()
por: Gartland, Alison, et al.
Publicado: (2016)